Citations

Clear

1100 citation(s) found for "Lewis, B".

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
Ryan, Charles J. , Tan, Alan , Watt, Colleen, Gartrell, Benjamin A. , Grubb, Robert L., Wen, Yujia , Rao, Arpit , Heller, Glenn , VanderWeele, David James , Lewis, Lionel D. , Chen, Ronald C. , Kohli, Manish , Barata, Pedro C. , Dueck, Amylou C. , Morris, Michael J.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS5107-TPS5107

10.1200/jco.2022.40.16_suppl.tps5107 Get It

TPS5107 Background: Despite a growing number of treatment options for first line mCRPC, approximately 40% of patients (pts) have radiographic progression within the first year. Androgen receptor (AR) signaling inhibition increases genomic instability with double-strand DNA breaks & co-inhibition of AR & PARP induces synthetic lethality in multiple preclinical models. Homologous recombination repair (HRR) gene aberrations do not appear to be necessary for this synergy as demonstrated in a ph 3 clinical trial of abiraterone & olaparib where this combination improved radiographic progression-free survival (rPFS) in HRR-wild-type pts compared with abiraterone alone. A ph 1b trial has since shown that enzalutamide plus rucaparib has acceptable safety profile & no significant drug-drug interactions (S-DDI). Methods: CASPAR/A031902 (NCT04455750) is a ph 3 study in which 984 pts will be randomized 1:1 to enzalutamide plus rucaparib or placebo. HRR gene aberration is not required for enrollment. All pts will undergo next-generation targeted-exome sequencing from archival tumor tissue (new biopsy only required if no archival tissue available). Treatment will be continued until disease progression & crossover is not allowed. Key eligibility criteria are age ≥ 18 years, ECOG PS 0-2, biopsy-proven prostate adenocarcinoma, progressive (PSA or radiographic) disease per Prostate Cancer Working Group 3 guidelines, measurable or nonmeasurable disease per RECIST 1.1, no prior treatment for mCRPC (prior docetaxel, abiraterone, darolutamide, or apalutamide in non-mCRPC setting is allowed), no significant uncontrolled comorbidity, & no medications with S-DDI with enzalutamide/rucaparib. Hierarchical co-primary endpoints are rPFS & overall survival (OS). The OS analysis will be undertaken as a primary endpoint if the rPFS endpoint is met. For a one-sided logrank test with a type 1 error rate equal to 0.025, the study has 90% power to detect a hazard ratio (HR) of 0.71 in rPFS (median rPFS of 15 & 21 months in control & combination arms, respectively) & 80% power to detect an HR of 0.80 in OS (median OS of 32 & 40 months, respectively). Key secondary endpoints are rPFS & OS in pts with vs without pathogenic BRCA1, BRCA2, or PALB2 alterations; & differences in adverse events & quality of life (QOL) outcomes between the treatment arms. QOL assessments include Functional Assessment of Cancer Therapy–Prostate (FACT-P), Brief Pain Inventory Short Form (BPI-SF) & EQ-5D-5L. A key correlative endpoint is the sensitivity of ctDNA-based testing for alterations in HRR genes. Enrollment to CASPAR began in July 2021 & the study is available for participation to all US-NCTN sites with a projected enrollment of 3 years. Support: U10CA180821, U10CA180882, U24CA196171; U10CA180888. Clinical trial information: NCT04455750.
Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19
Puranik, Arjun, O’Horo, John C. , Pawlowski, Colin , Virk, Abinash , Kremers, Walter K. , Breeher, Laura E. , Gordon, Joel , Geyer, Holly L. , Speicher, Leigh L. , Challener, Doug W, Breeher, Laura, Gordon, Joel E, Speicher, Leigh Lewis, O'Horo, John C , Kremers, Walter K , Lenehan, Patrick J. , Swift, Melanie D. , Venkatakrishnan, A J , Challener, Douglas W. , Breeher, Laura , Soundararajan, Venky , Badley, Andrew D.

Mayo Clinic

PNAS Nexus | May 21, 2022 | Volume: 1 | Issue: 2 | Pages: No page available

10.1093/pnasnexus/pgac058 | PMID 36713311 Get It

Abstract COVID-19 vaccines are effective, but breakthrough infections have been increasingly reported. We conducted a test-negative case-control study to assess the durability of protection against symptomatic infection after vaccination with mRNA-1273. We fit conditional logistic regression (CLR) models stratified on residential county and calendar date of SARS-CoV-2 PCR testing to assess the association between the time elapsed since vaccination and the odds of symptomatic infection, adjusted for several covariates. There were 2,364 symptomatic individuals who had a positive SARS-CoV-2 PCR test after full vaccination with mRNA-1273 (“cases”) and 12,949 symptomatic individuals who contributed 15,087 negative tests after full vaccination (“controls”). The odds of symptomatic infection were significantly higher 250 days after full vaccination compared to the date of full vaccination (Odds Ratio [OR]: 2.47, 95% confidence interval [CI]: 1.19–5.13). The odds of non-COVID-19 associated hospitalization and non-COVID-19 pneumonia (negative control outcomes) remained relatively stable over the same time interval (Day 250 ORNon-COVID Hospitalization: 0.68, 95% CI: 0.47–1.0; Day 250 ORNon-COVID Pneumonia: 1.11, 95% CI: 0.24–5.2). The odds of symptomatic infection remained significantly lower almost 300 days after the first mRNA-1273 dose as compared to 4 days after the first dose, when immune protection approximates the unvaccinated state (OR: 0.26, 95% CI: 0.17–0.39). Low rates of COVID-19 associated hospitalization or death in this cohort precluded analyses of these severe outcomes. In summary, mRNA-1273 robustly protected against symptomatic SARS-CoV-2 infection at least 8 months after full vaccination, but the degree of protection waned over this time period.
Abstract 47: Tapering And Discontinuation Of Background Therapies During The Transition To Rilonacept Monotherapy In Rhapsody, A Phase 3 Clinical Trial Of Rilonacept In Patients With Recurrent Pericarditis
Wheeler, Alistair, Abbate, Antonio , Fang, Fang , LeWinter, Martin M. , Lin, David , Chatfield, Jay B, Paolini, John F. , Brucato, Antonio , Wheeler, Alistair, Luis, Sushil Allen , Cremer, Paul , Insalaco, Antonella , Lewis, Basil S. , Nicholls, Stephen J. , Klein, Allan L. , Imazio, Massimo

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 12, 2022 | Volume: 15 | Issue: Suppl_1 | Pages: No page available

10.1161/circoutcomes.15.suppl_1.47 Get It

Background: Post-episode tapering of Standard of Care (SoC) medication in patients with recurrent pericarditis (RP) varies considerably. Gradual tapering of corticosteroids (CS) is recommended in ESC guidelines (decreasing by 1-2.5 mg/day every 2-6 weeks over 1-2 years) to prevent recurrence. We describe successful faster tapering of SoC treatment onto rilonacept monotherapy during RHAPSODY, a Phase 3, placebo-controlled, randomized-withdrawal (RW) trial in RP. Methods: Patients with acute symptomatic RP despite stable doses of NSAIDs, colchicine, and/or CS in any combination enrolled in a 12-week run-in period in which weekly rilonacept was initiated. After 1-week of stabilization, tapering of CS began at a rate dependent on baseline dose, to be completed by Week 10 for randomization at Week 12 when clinical response was confirmed by reduced pain and normalized CRP levels. Colchicine tapering/discontinuation was initiated no earlier than Week 4. This analysis evaluates time to rilonacept monotherapy in subgroups receiving different combinations of background therapies. Results: 79 of 86 patients were receiving pharmacotherapy at run-in baseline. Median (95% CI) time to monotherapy (n=79) was 7.9 (7.0-8.1) weeks. Of the patients receiving CS at baseline (41/86 [48%]), 39 (95%) tapered to rilonacept monotherapy, and median time to monotherapy was 7.9 (7.1-8.1) weeks. Of the patients receiving colchicine at baseline (65/86 [76%]), 61 (94%) patients achieved rilonacept monotherapy, and median time to monotherapy was 8.0 (7.1-8.3) weeks. Patients receiving only one SoC therapy achieved rilonacept monotherapy faster (6.1 [0.4-8.1] weeks) than those receiving 2 (8.0 [6.7-9.9] weeks) or 3 (7.7 [7.0-8.3] weeks) therapies. All patients who did not achieve monotherapy had withdrawn from the study for reasons unrelated to pericarditis. Conclusion: All patients randomized in the RHAPSODY trial discontinued SoC and transitioned to rilonacept monotherapy (median time 7.9 weeks) without a recurrent pericarditis episode during run-in. With rilonacept, time to successful discontinuation of SoC, including high dose CS, was substantially more rapid than current treatment practices. RHAPSODY data helped support FDA approval of the first therapy for RP.
Standardized Versus Tailored Implementation of Measurement-Based Care for Depression in Community Mental Health Clinics
Lewis, Cara C. , Marti, C. Nathan , Scott, Kelli , Walker, Madison R. , Boyd, Meredith R. , Puspitasari, Ajeng J. , Mendel, Peter , Boyd, Meredith, Puspitasari, Ajeng, Lewis, Cara C , Kroenke, Kurt

Mayo Clinic

Psychiatric Services | May 11, 2022 | Volume: 73 | Issue: 10 | Pages: 1094-1101

10.1176/appi.ps.202100284 | PMID 35538748 Get It

Rapid Exclusion of Acute Myocardial Injury and Infarction With a Single High-Sensitivity Cardiac Troponin T in the Emergency Department: A Multicenter United States Evaluation
Sandoval, Yader , Lewis, Bradley R., Mehta, Ramila A. , Ola, Olatunde , Knott, Jonathan D , Michieli, Laura De , Akula, Ashok , Lobo, Ronstan , Gharacholou, S. Michael , Dworak, Marshall , Crockford, Erika, Rastas, Nicholas, Grube, Eric , Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Jaffe, Allan S. , Lewis, Bradley R , De Michieli, Laura , Dworak, Marshall , Gulati, Rajiv , Jaffe, Allan S. , Yang, Eric H. , Grube, Eric

Mayo Clinic

Circulation | May 10, 2022 | Volume: 145 | Issue: 23 | Pages: 1708-1719

10.1161/circulationaha.122.059235 | PMID 35535607 Get It

Background: There are good data to support using a single high-sensitivity cardiac troponin T (hs-cTnT) below the limit of detection of 5 ng/L to exclude acute myocardial infarction. Per the US Food and Drug Administration, hs-cTnT can only report to the limit of quantitation of 6 ng/L, a threshold for which there are limited data. Our goal was to determine whether a single hs-cTnT below the limit of quantitation of 6 ng/L is a safe strategy to identify patients at low risk for acute myocardial injury and infarction. Methods: The efficacy (proportion identified as low risk based on baseline hs-cTnT<6 ng/L) of identifying low-risk patients was examined in a multicenter (n=22 sites) US cohort study of emergency department patients undergoing at least 1 hs-cTnT (CV Data Mart Biomarker cohort). We then determined the performance of a single hs-cTnT<6 ng/L (biomarker alone) to exclude acute myocardial injury (subsequent hs-cTnT >99th percentile in those with an initial hs-cTnT<6 ng/L). The clinically intended rule-out strategy combining a nonischemic ECG with a baseline hs-cTnT<6 ng/L was subsequently tested in an adjudicated cohort in which the diagnostic performance for ruling out acute myocardial infarction and safety (myocardial infarction or death at 30 days) were evaluated. Results: A total of 85 610 patients were evaluated in the CV Data Mart Biomarker cohort, among which 24 646 (29%) had a baseline hs-cTnT<6 ng/L. Women were more likely than men to have hs-cTnT<6 ng/L (38% versus 20%, P <0.0001). Among 11 962 patients with baseline hs-cTnT<6 ng/L and serial measurements, only 1.2% developed acute myocardial injury, resulting in a negative predictive value of 98.8% (95% CI, 98.6–99.0) and sensitivity of 99.6% (95% CI, 99.5–99.6). In the adjudicated cohort, a nonischemic ECG with hs-cTnT<6 ng/L identified 33% of patients (610/1849) as low risk and resulted in a negative predictive value and sensitivity of 100% and a 30-day rate of 0.2% for myocardial infarction or death. Conclusions: A single hs-cTnT below the limit of quantitation of 6 ng/L is a safe and rapid method to identify a substantial number of patients at very low risk for acute myocardial injury and infarction.
All That Is Miliary Is Not Tuberculosis: Fatal Disseminated Coccidioidomycosis in an Immunocompetent Patient
Roy, S. Biswas, Abdalla, A.A., Fanous, J., Wesselius, Lewis , Fanous, J.

Mayo Clinic

D107. SHOW US WHAT YOU'VE GOT: INTERESTING CASE REPORTS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5456-A5456

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5456 Get It

Disseminated Nocardiosis in an Immunocompetent Patient: An Often Overlooked Diagnosis in the Differential
Elwasila, Sammer M , LEWIS, KRISTYN L, Arunthari, V., Mendez, Julio, Colaco, B., Lewis, K.L.

Mayo Clinic

C60. ZEBRAS V. HORSES: UNUSUAL LUNG INFECTIONS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4488-A4488

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4488 Get It

A Challenging Diagnosis of Adult-Onset Asthma in a Patient with Congenital Agenesis of the Right Lung
Abdalla, A.A., Roy, S. Biswas, Wesselius, Lewis

Mayo Clinic

A65. PULMONARY CLINICAL CASES II | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A2042-A2042

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2042 Get It

Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma
Wongjarupong, Nicha , Yang, Lu , Johnson, Stephen , Yao, Janet , Harrington, Sean C., Nordyke, Cynthia K., Eaton, John E. , Gossard, Andrea A., Oli, Sharad , Ali, Hamdi A. , Lavu, Sravanthi , Giama, Nasra H., Hassan, Fatima, Ali, Hawa M. , Gores, Gregory J. , Topazian, Mark , Kashyap, Purna , Roberts, Lewis R. , Gores, Gregory J. , Yao, Janet Z, Hassan, Fatima A, Enders, Felicity T, Roberts, Lewis R , Miyabe, Katsuyuki , Chandrasekhara, Vinay , Chen, Jun , Chia, Nicholas , Walther-António, Marina , Enders, Felicity , Ilyas, Sumera I.

Mayo Clinic

Cancers | April 24, 2022 | Volume: 14 | Issue: 9 | Pages: 2120

10.3390/cancers14092120 | PMID 35565248 Get It

Background: Primary sclerosing cholangitis (PSC) is a major risk factor for cholangiocarcinoma (CCA). We investigated biliary and fecal microbiota to determine whether specific microbes in the bile or stool are associated with PSC or CCA. Methods: Bile was obtained from 32 patients with PSC, 23 with CCA with PSC, 26 with CCA without PSC, and 17 controls. Over 90% of bile samples were from patients with perihilar CCA. Stool was obtained from 31 patients with PSC (11 were matched to bile), 16 with CCA with PSC (10 matched to bile), and 11 with CCA without PSC (6 matched to bile). Microbiota composition was assessed using 16SrRNA-marker-based sequencing and was compared between groups. Results: Bile has a unique microbiota distinguished from negative DNA controls and stool. Increased species richness and abundance of Fusobacteria correlated with duration of PSC and characterized the biliary microbiota in CCA. Stool microbiota composition showed no significant differences between groups. Conclusions: We identified a unique microbial signature in the bile of patients with increased duration of PSC or with CCA, suggesting a role for microbiota-driven inflammation in the pathogenesis and or progression to perihilar CCA. Further studies are needed to test this hypothesis.
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States
Ahn, Joseph , Lauzon, Marie , Luu, Michael , Noureddin, Mazen , Ayoub, Walid S. , Kuo, Alexander , Sundaram, Vinay , Kosari, Kambiz , Nissen, Nicholas N. , Hendifar, Andrew , Roberts, Lewis R. , Yang, Ju Dong , Ahn, Joseph C , Singal, Amit , Yang, Ju Dong , Roberts, Lewis R , Gong, Jun , Abou‐Alfa, Ghassan K. , Singal, Amit G.

Mayo Clinic

Hepatology | April 16, 2022 | Volume: 76 | Issue: 6 | Pages: 1649-1659

10.1002/hep.32527 | PMID 35429171 Get It

Abstract Background and Aims Immunotherapy has emerged as an effective treatment for patients with advanced‐stage HCC. We aimed to investigate the efficacy of immunotherapy for advanced HCC in a nationwide cohort and racial and ethnic disparities in access to immunotherapy. Approach and Results We used the US National Cancer Database to identify patients with tumor‐node‐metastasis stage 3 or 4 HCC between 2017 and 2018. We performed multivariable Cox regression to identify factors associated with overall survival (OS) and logistic regression to identify factors associated with receipt of immunotherapy. Of the 3,990 patients treated for advanced HCC, 3,248 (81.4%) patients received chemotherapy and 742 (18.6%) patients received immunotherapy as a first‐line treatment. Immunotherapy was associated with improved OS compared with chemotherapy (adjusted HR: 0.76, 95% CI: 0.65–0.88) after adjusting for covariates. There were racial and ethnic disparities in access to immunotherapy, with Hispanic (adjusted OR [aOR]: 0.63, 95% CI: 0.46–0.83) and Black patients (aOR: 0.71, 95% CI: 0.54–0.89) less likely to receive immunotherapy compared with White patients. There was a significant interaction between race‐ethnicity and facility type, with higher disparity observed in nonacademic centers (interaction p = 0.004). Conclusions Immunotherapy was associated with improved OS compared with chemotherapy in advanced HCC. There are significant disparities in early access to immunotherapy, likely due to differential access to clinical trials and experimental therapies. A comprehensive approach to monitoring and eliminating racial‐ethnic disparities in the management of advanced HCC is urgently needed.